Status:
COMPLETED
Clinical Trial to Evaluate the Efficacy and Safety of Co-administration of JW0108+C2407 in Patients With Dyslipidemia
Lead Sponsor:
JW Pharmaceutical
Conditions:
Dyslipidemia
Eligibility:
All Genders
19+ years
Phase:
PHASE3
Brief Summary
A Multi-center, Randomized, Double-blind, Parallel, Phase Ⅲ Clinical Trial to Evaluate the Efficacy and Safety of Co-administration of JW0108+C2407 in Patients with Dyslipidemia
Detailed Description
To evaluate the efficacy and safety of JW0108+C2407 in dyslipidemia patients
Eligibility Criteria
Inclusion
- Age of 19 years old at the time of written informed consent
- Patients with dyslipidemia
Exclusion
- Secondary dyslipidemia
- Patient who does not meet the specified TG, LDL-C level
Key Trial Info
Start Date :
April 3 2025
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 30 2025
Estimated Enrollment :
145 Patients enrolled
Trial Details
Trial ID
NCT06955104
Start Date
April 3 2025
End Date
July 30 2025
Last Update
September 3 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Asan Medical Center
Seoul, South Korea, 05505